Prognostic value of the PrP^C-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype

References

• Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer. 2017;17(4):268. doi:10.1038/nrc.2017.24.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. Nature Medicine. 2015;21(11):1350–14. doi:10.1038/nm.3967.
   PubMed Web of Science ®Google Scholar
• Coebergh van den Braak RRJ, Ten HS, Sieuwerts AM, Tuynman JB, Smid M, Wilting SM, Martens JWM, Punt CJA, Foekens JA, Medema JP, et al. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. BMC Cancer. 2020;20(1):850. doi:10.1186/s12885-020-07316-z.
   PubMed Web of Science ®Google Scholar
• Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Selves J, Sautès-Fridman C, Laurent-Puig P, Fridman WH. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research. 2016;22(16):4057–4066. doi:10.1158/1078-0432.CCR-15-2879.
   PubMed Web of Science ®Google Scholar
• Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, et al. The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. EBioMedicine. 2019;46:94–104. doi:10.1016/j.ebiom.2019.07.036.
   PubMed Web of Science ®Google Scholar
• Calon A, Espinet E, Palomo-Ponce S, Tauriello DF, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung P, Zhang X-F, et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571–584. doi:10.1016/j.ccr.2012.08.013.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538–543. doi:10.1038/nature25492.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO in the Tumor Microenvironment: inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016;37(3):193–207. doi:10.1016/j.it.2016.01.002.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5):e1001453. doi:10.1371/journal.pmed.1001453.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Ghiringhelli F, Boige V, Le Malicot K, Taieb J, Bouché O, Phelip J-M, François E, Borel C, Faroux R, et al. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: a Randomized Phase III Trial (PRODIGE 9). Journal of Clinical Oncology. 2018;36(7):674–681. doi:10.1200/JCO.2017.75.2931.
   PubMed Web of Science ®Google Scholar
• Boulet L, Faure P, Flore P, Montérémal J, Ducros V. Simultaneous determination of tryptophan and 8 metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B. 2017;1054:36–43. doi:10.1016/j.jchromb.2017.04.010.
   PubMed Web of Science ®Google Scholar
• Bui T, Rennhack J, Mok S, Ling C, Perez M, Roccamo J, Andrechek ER, Moraes C, Muller WJ. Functional Redundancy between β1 and β3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer. Cell Rep. 2019;29(3):589–602.e6. doi:10.1016/j.celrep.2019.09.004.
   PubMed Web of Science ®Google Scholar
• Parvani JG, Galliher-Beckley AJ, Schiemann BJ, Schiemann WP, Luo K. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β. . Molecular Biology of the Cell. 2013;24(21):3449–3459. doi:10.1091/mbc.E12-10-0776.
   PubMed Web of Science ®Google Scholar
• Legate KR, Montañez E, Kudlacek O, Füssler FR. ILK, PINCH and parvin: the tIPP of integrin signalling. . Nature Reviews Molecular Cell Biology. 2006;7(1):20–31. doi:10.1038/nrm1789.
   PubMed Web of Science ®Google Scholar
• Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem J-L, Emile J-F, Mulot C, Fratté S, et al. Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients. . Annals of Oncology. 2017;28(4):824–830. doi:10.1093/annonc/mdw687.
   PubMed Web of Science ®Google Scholar
• Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature Communications. 2015;6(1):7002. doi:10.1038/ncomms8002.
   PubMed Web of Science ®Google Scholar
• Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M, Aben N, Ghavidel FZ, Michaut M, Schubert M, Price S, et al. Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells. Cell Rep. 2017;20(9):2201–2214. doi:10.1016/j.celrep.2017.08.010.
   PubMed Web of Science ®Google Scholar
• Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, et al. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research. 2018;24(4):794–806. doi:10.1158/1078-0432.CCR-17-1234.
   PubMed Web of Science ®Google Scholar
• Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 2006;66(1):393–403. doi:10.1158/0008-5472.CAN-05-2304.
   PubMed Web of Science ®Google Scholar
• Serrano I, McDonald PC, Lock F, Muller WJ, Dedhar S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nature Communications. 2013;4(1):2976. doi:10.1038/ncomms3976.
   PubMed Web of Science ®Google Scholar
• Oloumi A, Syam S, Dedhar S. Modulation of Wnt3a-mediated nuclear β-catenin accumulation and activation by integrin-linked kinase in mammalian cells. Oncogene. 2006;25(59):7747–7757. doi:10.1038/sj.onc.1209752.
   PubMed Web of Science ®Google Scholar
• Opitz CA, Somarribas Patterson LF, Mohapatra SR, Dewi DL, Sadik A, Platten M, Trump S. The therapeutic potential of targeting tryptophan catabolism in cancer. British Journal of Cancer. 2020;122(1):30–44. doi:10.1038/s41416-019-0664-6.
   PubMed Web of Science ®Google Scholar
• Soichot M, Hennart B, Al Saabi A, Leloire A, Froguel P, Levy-Marchal C, Poulain-Godefroy O, Allorge D, Chadwick BP. Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene. PloS One. 2011;6(9):e25470. doi:10.1371/journal.pone.0025470.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase – essential roles in physiology and cancer biology. Journal of Cell Science. 2008;121(19):3121–3132. doi:10.1242/jcs.017996.
   PubMed Web of Science ®Google Scholar
• Zheng -C-C, Hu H-F, Hong P, Zhang Q-H, Xu WW, He Q-Y, Li B. Significance of integrin-linked kinase (ILK) in tumorigenesis and its potential implication as a biomarker and therapeutic target for human cancer. American Journal of Cancer Research. 2019;9:186–197.
   PubMed Web of Science ®Google Scholar
• Tsoumas D, Nikou S, Giannopoulou E, Champeris Tsaniras S, Sirinian C, Maroulis I, Taraviras S, Zolota V, Kalofonos HP, Bravou V. ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance. Cancer Genomics Proteomics. 2018;15(2):127–141. doi:10.21873/cgp.20071.
   PubMed Web of Science ®Google Scholar
• Assi K, Mills J, Owen D, Ong C, St Arnaud R, Dedhar S, Salh B. Integrin-linked kinase regulates cell proliferation and tumour growth in murine colitis-associated carcinogenesis. Gut. 2008;57(7):931–940. doi:10.1136/gut.2007.142778.
   PubMed Web of Science ®Google Scholar
• Hirsch TZ, Martin-Lannerée S, Mouillet-Richard S. Functions of the Prion Protein. Prog. Mol. Biol. Transl. Sci 2017;150:1–34. doi:10.1016/bs.pmbts.2017.06.001.
   PubMed Web of Science ®Google Scholar
• Assi K, Patterson S, Dedhar S, Owen D, Levings M, Salh B. Role of epithelial integrin-linked kinase in promoting intestinal inflammation: effects on CCL2, fibronectin and the T cell repertoire. BMC Immunol. 2011;12(1):42. doi:10.1186/1471-2172-12-42.
   PubMed Web of Science ®Google Scholar
• Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, G√∂bel G, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clinical Cancer Research. 2006;12(4):1144–1151. doi:10.1158/1078-0432.CCR-05-1966.
   PubMed Web of Science ®Google Scholar
• Ferdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu A-M, Van Maerken T, Salmon I, Cuvelier CA, Demetter P. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. British Journal of Cancer. 2012;106(1):141–147. doi:10.1038/bjc.2011.513.
   PubMed Web of Science ®Google Scholar
• Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Molecular Cancer Therapeutics. 2010;9(2):489–498. doi:10.1158/1535-7163.MCT-09-0628.
   PubMed Web of Science ®Google Scholar
• Bishnupuri KS, Alvarado DM, Khouri AN, Shabsovich M, Chen B, Dieckgraefe BK, Ciorba MA. IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis. Cancer Res. 2019;79(6):1138–1150. doi:10.1158/0008-5472.CAN-18-0668.
   PubMed Web of Science ®Google Scholar
• Venkateswaran N, Lafita-Navarro MC, Hao Y-H, Kilgore JA, Perez-Castro L, Braverman J, Borenstein-Auerbach N, Kim M, Lesner NP, Mishra P, et al. MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. Genes Dev. 2019;33(17–18):1236–1251. doi:10.1101/gad.327056.119.
   PubMed Web of Science ®Google Scholar
• Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. British Journal of Cancer. 2002;86(11):1691–1696. doi:10.1038/sj.bjc.6600336.
   PubMed Web of Science ®Google Scholar
• Cavia-Saiz M, Muñiz Rodríguez P, Llorente Ayala B, García-González M, Coma-Del Corral MJ, García Girón C. The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer. Molecular Biology Reports. 2014;41(4):2275–2279. doi:10.1007/s11033-014-3080-2.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014;3(10):e957994. doi:10.4161/21624011.2014.957994.
   PubMed Web of Science ®Google Scholar
• Gomes B, Driessens G, Bartlett D, Cai D, Cauwenberghs S, Crosignani S, Dalvie D, Denies S, Dillon CP, Fantin VR, et al. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy. Molecular Cancer Therapeutics. 2018;17(12):2530–2542. doi:10.1158/1535-7163.MCT-17-1104.
   PubMed Web of Science ®Google Scholar